Overview Dividends

(CL) Colgate-Palmolive - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1941621039

Toothpaste, Soap, Pet Food, Shampoo, Cleaner

Household Products
Market Cap in USD: 63,332m
IPO / Inception: 1977-01-03
Return 12m vs S&P 500: -23.9%

EPS (Earnings per Share)

EPS (Earnings per Share) of CL over the last years for every Quarter: "2020-12": 0.77, "2021-03": 0.8, "2021-06": 0.8, "2021-09": 0.81, "2021-12": 0.79, "2022-03": 0.74, "2022-06": 0.72, "2022-09": 0.74, "2022-12": 0.77, "2023-03": 0.73, "2023-06": 0.77, "2023-09": 0.86, "2023-12": 0.87, "2024-03": 0.86, "2024-06": 0.91, "2024-09": 0.91, "2024-12": 0.91, "2025-03": 0.91, "2025-06": 0.92, "2025-09": 0.91,
EPS CAGR: 3.84%
EPS Trend: 88.8%
Last SUE: 0.00
Qual. Beats: 0

Revenue

Revenue of CL over the last years for every Quarter: 2020-12: 4324, 2021-03: 4344, 2021-06: 4260, 2021-09: 4414, 2021-12: 4403, 2022-03: 4399, 2022-06: 4484, 2022-09: 4455, 2022-12: 4629, 2023-03: 4770, 2023-06: 4822, 2023-09: 4915, 2023-12: 4950, 2024-03: 5065, 2024-06: 5058, 2024-09: 5033, 2024-12: 4944, 2025-03: 4911, 2025-06: 5110, 2025-09: 5131,
Rev. CAGR: 4.16%
Rev. Trend: 91.5%
Last SUE: 0.05
Qual. Beats: 0

Dividends

Dividend Yield 2.58%
Yield on Cost 5y 2.71%
Yield CAGR 5y 3.14%
Payout Consistency 96.1%
Payout Ratio 56.4%
Risk via 5d forecast
Volatility 19.0%
Value at Risk 5%th 31.5%
Relative Tail Risk 0.54%
Reward TTM
Sharpe Ratio -0.68
Alpha -15.89
CAGR/Max DD 0.10
Character TTM
Hurst Exponent 0.336
Beta 0.040
Beta Downside -0.063
Drawdowns 3y
Max DD 29.05%
Mean DD 9.95%
Median DD 8.21%

Description: CL Colgate-Palmolive December 02, 2025

Colgate-Palmolive (NYSE: CL) manufactures and sells a broad portfolio of oral, personal, home-care, and pet-nutrition products worldwide, organized into two operating segments: Oral, Personal & Home Care and Pet Nutrition. The consumer-care segment leverages well-known brands such as Colgate, Palmolive, Tom’s of Maine, Irish Spring, and Ajax, serving traditional retailers, e-commerce platforms, dentists and skin-health professionals, while the Pet Nutrition segment markets Hill’s Science Diet and Hill’s Prescription Diet through pet-supply stores, veterinarians and online channels.

Key recent metrics: FY 2023 net sales reached approximately $17.4 billion, with an adjusted operating margin of roughly 15 % and a dividend yield near 2.6 %, reflecting the company’s stable cash-flow generation in the defensive consumer-staples sector. Growth is being driven by price-inflation pass-throughs in emerging markets and a shift toward premium, health-focused products, while rising raw-material costs and global supply-chain constraints remain material risks.

If you want a data-driven deep-dive into CL’s valuation and forward-looking assumptions, a quick look at ValueRay’s analyst toolkit can provide useful context.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (2.91b TTM) > 0 and > 6% of Revenue (6% = 1.21b TTM)
FCFTA 0.20 (>2.0%) and ΔFCFTA -0.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -2.27% (prev 1.20%; Δ -3.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.23 (>3.0%) and CFO 4.01b > Net Income 2.91b (YES >=105%, WARN >=100%)
Net Debt (7.14b) to EBITDA (4.81b) ratio: 1.48 <= 3.0 (WARN <= 3.5)
Current Ratio 0.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (810.2m) change vs 12m ago -1.50% (target <= -2.0% for YES)
Gross Margin 60.15% (prev 60.29%; Δ -0.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 117.2% (prev 119.9%; Δ -2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 15.57 (EBITDA TTM 4.81b / Interest Expense TTM 270.0m) >= 6 (WARN >= 3)

Altman Z'' 8.10

(A) -0.03 = (Total Current Assets 6.04b - Total Current Liabilities 6.50b) / Total Assets 17.51b
(B) 1.54 = Retained Earnings (Balance) 27.05b / Total Assets 17.51b
warn (B) unusual magnitude: 1.54 — check mapping/units
(C) 0.25 = EBIT TTM 4.20b / Avg Total Assets 17.14b
(D) 1.51 = Book Value of Equity 24.63b / Total Liabilities 16.27b
Total Rating: 8.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 82.01

1. Piotroski 5.50pt
2. FCF Yield 4.89%
3. FCF Margin 17.13%
4. Debt/Equity 9.84
5. Debt/Ebitda 1.48
6. ROIC - WACC (= 31.04)%
7. RoE 545.1%
8. Rev. Trend 91.48%
9. EPS Trend 88.79%

What is the price of CL shares?

As of December 28, 2025, the stock is trading at USD 79.73 with a total of 2,934,998 shares traded.
Over the past week, the price has changed by +1.75%, over one month by -0.39%, over three months by +0.85% and over the past year by -11.60%.

Is CL a buy, sell or hold?

Colgate-Palmolive has received a consensus analysts rating of 3.77. Therefor, it is recommend to hold CL.
  • Strong Buy: 7
  • Buy: 6
  • Hold: 7
  • Sell: 1
  • Strong Sell: 1

What are the forecasts/targets for the CL price?

Issuer Target Up/Down from current
Wallstreet Target Price 87.3 9.5%
Analysts Target Price 87.3 9.5%
ValueRay Target Price 81.8 2.5%

CL Fundamental Data Overview December 28, 2025

Market Cap USD = 63.33b (63.33b USD * 1.0 USD.USD)
P/E Trailing = 21.9496
P/E Forward = 20.1207
P/S = 3.1513
P/B = 73.1956
P/EG = 3.0017
Beta = 0.295
Revenue TTM = 20.10b USD
EBIT TTM = 4.20b USD
EBITDA TTM = 4.81b USD
Long Term Debt = 7.31b USD (from longTermDebt, last quarter)
Short Term Debt = 1.11b USD (from shortTermDebt, last quarter)
Debt = 8.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.14b USD (from netDebt column, last quarter)
Enterprise Value = 70.47b USD (63.33b + Debt 8.42b - CCE 1.28b)
Interest Coverage Ratio = 15.57 (Ebit TTM 4.20b / Interest Expense TTM 270.0m)
FCF Yield = 4.89% (FCF TTM 3.44b / Enterprise Value 70.47b)
FCF Margin = 17.13% (FCF TTM 3.44b / Revenue TTM 20.10b)
Net Margin = 14.47% (Net Income TTM 2.91b / Revenue TTM 20.10b)
Gross Margin = 60.15% ((Revenue TTM 20.10b - Cost of Revenue TTM 8.01b) / Revenue TTM)
Gross Margin QoQ = 59.42% (prev 60.06%)
Tobins Q-Ratio = 4.02 (Enterprise Value 70.47b / Total Assets 17.51b)
Interest Expense / Debt = 0.80% (Interest Expense 67.0m / Debt 8.42b)
Taxrate = 22.78% (226.0m / 992.0m)
NOPAT = 3.25b (EBIT 4.20b * (1 - 22.78%))
Current Ratio = 0.93 (Total Current Assets 6.04b / Total Current Liabilities 6.50b)
Debt / Equity = 9.84 (Debt 8.42b / totalStockholderEquity, last quarter 856.0m)
Debt / EBITDA = 1.48 (Net Debt 7.14b / EBITDA 4.81b)
Debt / FCF = 2.07 (Net Debt 7.14b / FCF TTM 3.44b)
Total Stockholder Equity = 533.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.60% (Net Income 2.91b / Total Assets 17.51b)
RoE = 545.1% (Net Income TTM 2.91b / Total Stockholder Equity 533.2m)
RoCE = 53.63% (EBIT 4.20b / Capital Employed (Equity 533.2m + L.T.Debt 7.31b))
RoIC = 36.55% (NOPAT 3.25b / Invested Capital 8.88b)
WACC = 5.51% (E(63.33b)/V(71.75b) * Re(6.16%) + D(8.42b)/V(71.75b) * Rd(0.80%) * (1-Tc(0.23)))
Discount Rate = 6.16% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.91%
[DCF Debug] Terminal Value 79.70% ; FCFE base≈3.43b ; Y1≈3.79b ; Y5≈4.93b
Fair Price DCF = 106.4 (DCF Value 85.73b / Shares Outstanding 806.1m; 5y FCF grow 12.34% → 3.0% )
EPS Correlation: 88.79 | EPS CAGR: 3.84% | SUE: 0.0 | # QB: 0
Revenue Correlation: 91.48 | Revenue CAGR: 4.16% | SUE: 0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.94 | Chg30d=-0.001 | Revisions Net=-8 | Analysts=12
EPS next Year (2026-12-31): EPS=3.84 | Chg30d=+0.002 | Revisions Net=-1 | Growth EPS=+5.0% | Growth Revenue=+3.4%

Additional Sources for CL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle